I. Pharmacodynamics Assays
A. Definition B. History
1. Impact of Phase 0 Legislation 2. SBIR Support of Pharmacodynamic Assay Development
C. Increasing Participation from Research Supply Companies
1. Natural Extension of Product Lines 2. A Response to Potential Profits
II. Market Segmentation of by Application
A. Streamlined Drug Development Processes for Pharmaceutical Companies B. Phase 0 Clinical Trials C. Patient Stratification during Clinical Trials (Phase I-IV) D. Prediction of Cancer Re-Occurrence E. Insights into the Basis of Cytotoxic Response to Existing Cancer Therapies F. Pharmacodynamic Monitoring of Immunosuppressive Drugs
III. Market Environment
A. High Market Penetration Assays B. Recently Validated Assays C. Assays under Development
IV. High-priority Molecular Targets for Assay Development
V. Competitive Analysis
A. Early Entrants B. Dominant Competitors C. Recent Market Players
VI. Analysis of Grant Rates / Trends in Funding
A. Trailing 5 Year Analysis B. Projected 5 Year Analysis
VII. Market Size Determination for Pharmacodynamic Assays
A. Methods B. Worldwide Annual Market Size C. U.S. Annual Market Size
VIII. Market Growth Rates & Trend Analysis
A. Experimental Approach B. Growth Rates C. Trend Analysis
IX. Market Projections
X. Product Development Opportunities & Suggestions
A. Pre-Clinical Applications (Research-Use Only)
1. Angiogenesis 2. DNA Damage/Apoptosis 3. Other
B. Clinical Applications |